Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study

被引：0
|
作者：
William B. Young
J. Ivan Lopez
John F. Rothrock
Amelia Orejudos
Aubrey Manack Adams
Richard B. Lipton
Andrew M. Blumenfeld
机构：
[1] Jefferson Hospital for Neuroscience,
[2] University of South Alabama College of Medicine,undefined
[3] George Washington School of Medicine,undefined
[4] Allergan plc,undefined
[5] Montefiore Headache Center,undefined
[6] Department of Neurology,undefined
[7] Department of Epidemiology and Population Health,undefined
[8] Albert Einstein College of Medicine,undefined
[9] Headache Center of Southern California,undefined
[10] The Neurology Center,undefined
来源：
The Journal of Headache and Pain | 2019年 / 20卷
关键词：
COMPEL; Daily headache; Disability; Migraine; OnabotulinumtoxinA; Quality of life;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL
    Blumenfeld, Andrew
    Stark, Richard
    Adams, Aubrey Manack
    Orejudos, Amelia
    Aurora, Sheena
    NEUROLOGY, 2017, 88
  • [32] The Long-Term Efficacy and Safety of OnabotulinumtoxinA for the Prevention of Chronic Migraine in Patients with Medication Overuse: Results of the COMPEL Study
    Tepper, S. J.
    Wilson, M.
    Orejudos, A.
    Adams, Manack A.
    Blumenfeld, A.
    HEADACHE, 2018, 58 : 93 - 94
  • [33] The long-term efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine in patients with medication overuse: results of the COMPEL study
    Tepper, S.
    Wilson, M. -C.
    Orejudos, A.
    Adams, A. Manack
    Blumenfeld, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 78 - 78
  • [34] Comparison of the efficacy of onabotulinumtoxinA in new daily persistent headache to chronic migraine
    Cheema, Sanjay
    Lagrata, Susie
    Ahmed, Maha
    Kamourieh, Salwa
    Matharu, Manjit
    CEPHALALGIA, 2023, 43 (1supp) : 281 - 281
  • [35] OnabotulinumtoxinA for primary new daily persistent headache and comparison to chronic migraine
    Cheema, Sanjay
    Lagrata, Susie
    Rantell, Khadija Rerhou
    Ahmed, Maha
    Kamourieh, Salwa
    Matharu, Manjit Singh
    CEPHALALGIA, 2025, 45 (02)
  • [36] Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Chronic Migraine Patients: COMPEL Analysis by Treatment Cycle
    Winner, P. K.
    Blumenfeld, A.
    Eross, E. J.
    Orejudos, A.
    Adams, Manack A.
    Brin, M. F.
    HEADACHE, 2018, 58 : 105 - 105
  • [37] Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Chronic Migraine Patients: COMPEL Analysis by Treatment Cycle
    Winner, Paul K.
    Blumenfeld, Andrew M.
    Eross, Eric J.
    Orejudos, Amelia
    Adams, Aubrey Manack
    Brin, Mitchell F.
    CEPHALALGIA, 2017, 37 : 93 - +
  • [38] Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Chronic Migraine Patients: COMPEL Analysis by Treatment Cycle
    Brin, Mitchell F.
    Winner, Paul
    Blumenfeld, Andrew M.
    Eross, Eric J.
    Orejudos, Amelia
    Adams, Aubrey Manack
    NEUROLOGY, 2018, 90
  • [39] OnabotulinumtoxinA for Treatment of Chronic Migraine: 56-Week Analysis of the PREEMPT Chronic Migraine Subgroup with Baseline Acute Headache Medication Overuse
    Silberstein, Stephen D.
    Saper, Joel R.
    Stein, Michael R.
    DeGryse, Ronald E.
    Turkel, Catherine C.
    NEUROLOGY, 2010, 74 (09) : A397 - A397
  • [40] Effects of OnabotulinumtoxinATreatment on Disability and Quality of Life in Patients with Chronic Migraine with Baseline Allodynia: A COMPEL Subanalysis
    Young, W. B.
    Lopez, J.
    Rothrock, J. F.
    Manack, Adams A.
    Blumenfeld, A. M.
    HEADACHE, 2017, 57 : 170 - 171
12345